Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 in Obesity or Overweight With Comorbidity
NCT06595238Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 5
01
Overview
A Phase 2 trial of lenbelintide in obesity, sponsored by AstraZeneca. Started Oct 2024; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06595238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595238.